CapitaLand Investment (SGX:9CI) stock ends week higher — what to watch before Feb 11 results

Singapore, Jan 10, 2026, 14:57 SGT — Market closed

CapitaLand Investment Limited (SGX:9CI) saw its shares climb 1.8% to finish at S$2.89 on Friday, up from S$2.84 the previous session. The stock fluctuated between S$2.84 and S$2.92 during the day. Trading volume hit roughly 20.4 million shares. (Yahoo Finance)

With the Singapore market closed for the weekend, focus now turns to full-year results set for release on Feb 11 before the open, according to an SGX notice. Ahead of those, several CLI-managed listed funds will report, starting with CapitaLand Malaysia Trust on Jan 28, followed by CapitaLand Ascott Trust on Jan 29. (SGX Links)

CLI announced on Thursday plans to develop a S$260 million automated logistics hub in Singapore via its CapitaLand South-east Asia Logistics Fund, targeting completion by 2028. The company also secured a minority stake in smart logistics firm Ally Logistic Property, which will operate the facility under a master lease featuring built-in rent increases, The Business Times reported.

The broader market held steady. Singapore’s Straits Times Index ticked up 0.1% on Jan 9 as regional markets gained ground. Traders kept an eye on a potential U.S. Supreme Court decision related to President Donald Trump’s tariffs. “Tariffs are not going anywhere,” said Neil Wilson, UK investment strategist at Saxo Markets. (The Straits Times)

Behind the scenes, the Monetary Authority of Singapore is seeking input on legal reforms designed to simplify dual listings on SGX and Nasdaq. This includes a proposed safe-harbour framework for share buybacks. The consultation is part of a wider effort to attract more issuers and boost trading activity. (Reuters)

Investors in CLI will focus on clear updates around fundraising, fee income, and the speed of capital recycling into key targets like logistics. After the recent rally, the stock is now testing last week’s highs, and a move above that level could attract fresh short-term buying.

The upside hinges on the cycle holding steady. Any drop in trade, stubbornly high rates, or turbulence in property funding could hit demand for new logistics space and pinch returns, even in “new economy” warehouses. Plus, long construction timelines add plenty of execution risk.

Shan Ahmed Khan Latest posts

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

View all

GSK still undervalued after 46% rise, DCF points to upside
January 10, 2026, 5:36 PM EST. GSK trades around £18.86 after roughly a 46% rise over the past year, as investors reassess the risk-reward profile of its core pharma and vaccines business amid its split from consumer health. A Simply Wall St valuation gives a 5/6 value score, and its DCF analysis points to a meaningful upside. The model yields an intrinsic value of £43.59 a share, implying the stock is about 56.7% undervalued at current levels. Using a two-stage Free Cash Flow to Equity approach, analysts assume FCF rises to about £9.4b in 2035, with intermediate years around £6-8b. The stock's P/E of 13.8x trails the Pharmaceuticals industry average of 22.9x and peer average of 17.7x. The numbers suggest the market hasn't fully priced in potential value from the pipeline and separation.